+919405117673
Dasatinib 70mg Tablets – Trusted Global Exporter from India | Fast Delivery to USA, UK, UAE & More
Dasatinib 70mg Tablets are a widely prescribed targeted therapy used in the treatment of certain types of leukemia, including chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL). As a leading global pharmaceutical exporter, Cordium Pharmaceuticals Pvt Ltd ensures high-quality, affordable oncology medicines with fast and secure international delivery.

🌍 Global Supply & Fast Delivery

Cordium Pharmaceuticals Pvt Ltd specializes in exporting Dasatinib 70mg Tablets from India to countries including the United States, Germany, United Kingdom, Netherlands, South Africa, United Arab Emirates, and Brazil. With a strong logistics network, we guarantee timely and reliable shipments worldwide.

πŸ’Š Uses of Dasatinib 70mg Tablets

Dasatinib is a tyrosine kinase inhibitor (TKI) used for:

Treatment of Chronic Myeloid Leukemia (CML)
Treatment of Philadelphia chromosome-positive Acute Lymphoblastic Leukemia (Ph+ ALL)
Patients resistant or intolerant to prior therapies
πŸ“Œ Dosage & Administration
The typical recommended dose is 70mg once or twice daily, depending on the condition and medical advice.
Should be taken with or without food, at the same time each day.
Dosage adjustments may be required based on patient response and side effects.
Always follow your healthcare provider’s prescription strictly.
⚠️ Possible Side Effects

Like all medications, Dasatinib may cause side effects. Common ones include:

Nausea and vomiting
Fatigue or weakness
Headache
Diarrhea
Skin rash

Serious side effects (seek medical attention):

Breathing difficulty or fluid retention
Low blood cell counts
Bleeding or bruising easily
Heart-related complications
βœ… Why Choose Cordium Pharmaceuticals Pvt Ltd?
WHO-GMP compliant sourcing
Competitive global pricing
Fast international shipping
Trusted oncology medicine exporter
Reliable customer support
πŸ“ž Contact for Global Orders

πŸ“± WhatsApp: +91-9405117673
πŸ“§ Email: info@cordiumpharma.com
Apr 18th, 2026 8:02 PM

Keywords